NCT04341389View on ClinicalTrials.gov

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

PHASE2CompletedINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

April 12, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

December 31, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)

Intramuscular injection

OTHER

Placebo

Intramuscular injection

Trial Locations (1)

Unknown

Hubei Provincial Center for Disease Control and Prevention, Wuhan

Sponsors

Collaborators (1)

CanSino Biologics Inc.
All Listed Sponsors
collaborator

CanSino Biologics Inc.

INDUSTRY

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

collaborator

Hubei Provincial Center for Disease Control and Prevention

OTHER

collaborator

Zhongnan Hospital

OTHER

lead

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

OTHER

NCT04341389 - A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) | Biotech Hunter | Biotech Hunter